Overview

A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer

Status:
Completed

Trial end date:
2011-10-01

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to determine the 2-year survival rate of both of the chemotherapy regimens in patients with inoperable non-small-cell lung cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Carboplatin
Cisplatin
Pemetrexed